Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Guggenheim. They set a "buy" rating and a $19.00 price target on the stock.
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.